Viatris Inc (VTRS) financials — revenue, cash, debt and margins

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $20.8B
P/E (TTM): —
Price / sales: 1.41
EV / EBITDA: 12.18
Price / book: 1.46

Cash flow

FCF yield: 9.4%
SBC-adjusted FCF yield: 8.6%
SBC impact: 8.8%
Stock compensation (TTM): $172.3M

Margins & growth

Profit margin: -23.9%
Operating margin: -0.6%
Quarterly revenue (year on year): 4.9%
Quarterly earnings (year on year): —

Balance sheet

Cash & investments: $1.4B
Debt: $13.6B
Net cash / (debt): -$12.3B

Where the revenue comes from

Brands is 64% of revenue.

By product or service

Year to Dec 31, 2025 · $14.3B

Brands64%
$9.2B-0.2% vs. a year earlier
Lipitor11%
$1.5B+5.5% vs. a year earlier
Norvasc5%
$709.9M+5.4% vs. a year earlier
Epi Pen Auto Injectors3%
$469.7M+19.8% vs. a year earlier
Viagra3%
$408.2M+3.2% vs. a year earlier
Creon3%
$365.8M+11.5% vs. a year earlier
Celebrex2%
$272.9M-4.4% vs. a year earlier
Yupelri2%
$266.9M+11.9% vs. a year earlier
Effexor2%
$257.7M+1.9% vs. a year earlier
Influvac1%
$194.4M+8.8% vs. a year earlier
Dymista1%
$163.6M-13.0% vs. a year earlier
Xalabrands1%
$158.4M-4.8% vs. a year earlier
Amitiza1%
$158.1M+6.0% vs. a year earlier
Xanax1%
$139.9M-3.5% vs. a year earlier

By business segment

Year to Dec 31, 2025 · $14.3B

Developed Markets60%
$8.6B-4.6% vs. a year earlier
Greater China16%
$2.3B+7.6% vs. a year earlier
Emerging Markets16%
$2.2B-1.9% vs. a year earlier
Japan Australia and New Zealand8%
$1.2B-11.3% vs. a year earlier

By region

Year to Dec 31, 2025 · $5.1B

United States59%
$3B-12.5% vs. a year earlier
China41%
$2.1B+8.8% vs. a year earlier

These lines are the breakdown as filed. We could not reconcile them against the total revenue for the same period.

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$14.74BQ2 2026+1.2%

1Y: +4.40%2Y: -3.29%5Y: -5.55%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

EBITDA

$2.72BQ2 2026-7.9%

1Y: +1,643.52%2Y: -1.66%5Y: -17.22%

Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

-$3.51B2025-454.2%-24.6% of revenue

No TTM figures — showing Yearly

What was left after every cost, including tax. One bar per fiscal year, as filed. Stops at the last completed year.

Profit margin

-24.6%2025-471.3%

No TTM figures — showing Yearly

How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. One point per fiscal year, as filed. Stops at the last completed year.

Free Cash Flow

$1.95BQ2 2026+9.0%

1Y: +11.61%2Y: -3.58%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

-$0.36Q2 2026-38.5%

1Y: +87.59%2Y: +33.33%5Y: +84.48%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.

Shares outstanding

1.2BQ3 2024-0.1%

How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.

Price to earnings

6.4xQ4 2023+14.6%

6.4x today · median 6.4x and range 4.8x–14.4x across the points shown, Q3 2022 to Q4 2023

Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.

Dividends paid

$133MQ3 2021

No TTM figures — showing Quarterly

Cash handed to shareholders. A flat line at zero means the company pays none. Each quarter on its own, so seasonal highs and lows are visible.

About Viatris Inc

Ticker: VTRS
SEC classification: Pharmaceutical Preparations (2834)
Listed on: Nasdaq
Incorporated in: DE
Financial year ends: December 31
Filer size: Large accelerated filer

About this data

Everything above comes from Viatris Inc’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Share-count jumps we cannot explain: 2.01x around Dec 31, 2021. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.

Not reported by this filer: Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Borrowings (total), Finance Lease (current), Finance Lease Liabilities (total), and Finance Lease (noncurrent). Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.